← Back to Search

Behavioural Intervention

Mobile App for Arthritis (RAPID-PsA Trial)

N/A

Recruiting

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Using guselkumab, infliximab, golimumab, or ustekinumab

At least 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to test a new version of a smartphone app for arthritis over 12 months. Researchers will compare how often people visit their healthcare providers before and after using the app. They will also compare

Who is the study for?

This trial is for adults over 18 with Psoriatic Arthritis (PsA), diagnosed by a specialist, who've had at least two appointments in the past year. Participants must speak English and own an Android or iPhone smartphone. They should be using specific arthritis medications like guselkumab or infliximab.

What is being tested?

The study tests if a new version of the Arthritis app can change how often patients need to visit doctors. It compares visit frequency before and after introducing the app, and against a control group not using the app, over 12 months.

What are the potential side effects?

Since this trial involves a mobile application rather than medication, traditional side effects are not expected. However, users may experience issues related to usability such as difficulty navigating the app or technical glitches.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently using guselkumab, infliximab, golimumab, or ustekinumab.

Select...

I am 18 years old or older.

Select...

I have been diagnosed with Psoriatic Arthritis by a specialist and have had at least two appointments in the last year.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Visit Frequency

Secondary study objectives

Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue short form

Patient Reported Outcomes Measurement Information System (PROMIS) Function short form

Patient Reported Outcomes Measurement Information System (PROMIS) Pain short form

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Mobile ApplicationExperimental Treatment1 Intervention

This arm of the study will contain half the study population after randomization. The participants in this arm will receive the EHR integrated app and follow a 12-month interrupted time series analysis (ITSA) design. n = 200

Group II: ControlsActive Control1 Intervention

This arm of the study will contain half the study population after randomization. The participants in this arm will be from the same rheumatologists as the experimental participants and will be used as concurrent controls by accessing their data on visits from the EHR during the same time period. n = 200

0 / 3Eligibility criteria met